Tilt Biotherapeutics, a Helsinki, Finland-based clinical-stage biotechnology company, raised $10.7M in funding.
The round was led by Lifeline Ventures with participation from Tesi. The company also announces the appointment of Dr. Tuija Keinonen, PhD (Pharm),as Chair of the Board.
The company intends to use the funds to advance Phase I/II programs in Europe and the US, using TILT-123 plus immune checkpoint inhibitors against a range of cancers including ovarian, head & neck, and lung.
Led by CEO Akseli Hemminki, Tilt Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules including cytokines that can stimulate, or suppress, T cells. The company’s patented TILT technology, which can be delivered locally and systemically, modifies the tumor microenvironment, and eliminates its ability to suppress immune responses to cancer, thereby enhancing T-cell therapies such as checkpoint inhibitors and CAR T therapies.
Tilt’s lead asset, TILT-123, is a 5/3 chimeric serotype adenovirus armed with two human cytokines: TNF alpha and IL-2. TILT-123 has demonstrated a 100% response rate in pre-clinical cancer models in vivo, and it is currently in Phase 1 clinical trials.